Optimizing Therapy for Endometrial Cancer: Recent Data Highlights - Episode 9

Endometrial Cancer: Managing Toxicities in Lenvatinib and Pembrolizumab

,

Discover strategies for minimizing adverse events and overlapping toxicities in patients undergoing lenvatinib and pembrolizumab therapy for recurrent endometrial cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Changing Landscape of Endometrial Cancer: Incidence and Classification
    EP. 2: Optimal Workup Strategies in Advanced Endometrial Cancer
    EP. 3: Factors in Frontline Treatment Decision Making for Endometrial Cancer
    EP. 4: Assessing Response to First-Line Therapy in Advanced Endometrial Cancer: Clinical Factors
    EP. 5: Chronic Challenges in Endometrial Cancer: Recurrence and Second-Line Therapy
    EP. 6: Treatment Choices for Recurrent dMMR Endometrial Cancer
    EP. 7: HER2-Positive Endometrial Cancer: A Targeted Approach to Treatment
    EP. 8: Treatment for Recurrent Endometrial Cancer: Chemotherapy or Lenvatinib + Pembrolizumab
    Now Viewing
    EP. 9: Endometrial Cancer: Managing Toxicities in Lenvatinib and Pembrolizumab
    EP. 10: Revolutionizing Frontline Therapy for Endometrial Cancer: Checkpoint Inhibitors and MMR Status
    EP. 11: Expanding Horizons in Endometrial Cancer Treatment: Beyond Chemotherapy
    EP. 12: Diversity and Access to Clinical Trials in Endometrial Cancer
    x